SYK and leukemia: However, additional targeted SYK inhibition or dual FLT3/SYK inhibition potentiates the effects of midostaurin and other inhibitors of FLT3 against both kinase inhibitor-sensitive- and -resistant FLT3-ITD- and activated SYK-positive leukemia.